Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Dermpath > Inflammatory Lesions > Flashcards

Inflammatory Lesions Flashcards

1
Q

Scabies

A. Etiologic agent
B. Incubation period
C. Treatment

A

A. Sarcoptes scabiei

B. 4-6 weeks

C. Permethrin 5% lotion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Molluscum contagiosum

A. Incubation period
B. Etiologic agent

A

A. 2-7 weeks

B. Pox virus
MCV1 - most common
MCV2 - adults and immunocompromised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Verruca vulgaris

A. Incubation period
B. Etiologic agent

A

A. 2-9 months

B. Human papillomavirus
HPV 1: palmar/plantar
HPV 2, 4: common warts
HPV 3, 10: flat warts
HPV 7: butcher’s
HPV 5, 8: EV
HPV 6, 11, 16, 18: anogenital

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Chromomycosis

A. Etiologic agent
B. Stain
C. Characteristic histologic finding

A

A. Fonsecaea, Cladosporium, Phialophora

B. Periodic Acid Schiff (PAS), Grocott’s Methenamine Silve (GMS)

C. Copper pennies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mycetoma

A. Etiologic agent
B. What do you call the eosinophilic rim surrounding the granule

A

A. Eumycetoma: Madurella mycetomatis (fungal)
Actinomycetoma: Nocardia braziliensis (bacteria)

B. Splendore Hoeppli phenomenon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pityriasis versicolor

A. Etiologic agent
B. Stain

A

A. Malassezia globosa or furfur

B. PAS, GMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dermatophytosis

A. Common etiologic agent/s
B. Stain

A

A. Trichophyton and Microsporum

B. GMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tuberculosis verrucosa cutis

A. Pathogenesis
B. Level of immunity

A

A. Reinfection of immune patients

B. High cell mediated immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lupus vulgaris

A. Mechanism of spread
B. Level of immunity

A

A. Hematogenous or lymphatic

B. Moderate to high immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lepromatous leprosy

A. Level of immunity
B. Etiologic agent
C. Stain
D. Types of reversal reactions
E. Treatment

A

A. Poor cell mediated immunity

B. Mycobacterium leprae

C. Fite-faraco, Auramine Rhodamine (gold)

D. Type 1: BT/BB/BL
Type 2 (ENL): LL

E. Rifampicin 600mg/month x 12 months
Dapsone 100mg/day x 12 months
Clofazimine 300mg/month and 50mg/day x 12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tuberculoid leprosy

A. Level of immunity
B. Stain
C. Treatment

A

A. High cell mediated immunity

B. (-) Fite-faraco, absent M. leprae

C. Rifampicin 600mg/month x 6 months
Dapsone 100mg/day x 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Subcutaneous Fat Necrosis of the Newborn

A. Pathogenesis
B. Complication

A

A. Hypoxic injury to fat

B. Hypercalcemia - screen for the first 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Erythema Induratum

A. Disease association
B. Site of predilection
C. Tests

A

A. Tuberculosis

B. Calves

C. PPD, Quantiferon gold

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Erythema nodosum

A. Disease association
B. Predilection site

A

A. Streptococcal, OCP, Sarcoidosis

B. Pretibial area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Polyarteritis nodosa

A. Size of involved vessel
B. Clinical manifestations

A

A. Medium vessel vasculitis

B. Livedo reticularis, Subcutaneous nodules, Ulceration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Rosacea

A. Etiologic agent
B. Triggers

A

A. Demodex mite

B. Sunlight, heat/cold, stress, strong emotions, alcohol, hot beverages, spicy food, chemical irritation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Mastocytosis

A. Mutation
B. Stain

A

A. C-Kit

B. Leder, Giemsa, Toluidine blue, Tryptase, CD117/cKit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lichen amyloidosis

A. Deposit
B. Stain

A

A. Altered keratin

B. Congo red (apple-green polarization), Thioflavin (yellow/fluorescent), Crystal violet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Causes of ochronosis

A

Exogenous: Hydroquinone, Phenolic acid

Endogenous: Alkaptonuria (Homogentisic acid accumulation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Stain for hypertrophic scars and keloid

A

Verhoeff-Van Gieson (loss of elastic fibers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Stain for morphea

A

Reduced number of CD34+ cells in the dermis

Verhoeff-Van Gieson (preservation of elastic fibers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Cutaneous lymphoma

A. Most common subgroup
B. Age of predilection
C. Stain

A

A. Mycosis fungoides/CTCL

B. 75% diagnosed after 50yo

C. CD4 > CD8 T cell
CD3 T cell
CD30 (large atypical T cells) - also in LyP
CD20 B cells
Bcl-6 germinal B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Lichen sclerosus et atrophicus

A. Autoantigen
B. Associated malignancy
C. Stain
D. Treatment

A

A. Autoantibody against ECM1 (same with lipoid proteinosis)

B. 5% risk for SCC

C. Masson Trichrome

D. Ultrapotent topical steroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Characteristic clinical finding of erythema annulare centrifigum

A

Trailing scale - inner desquamation

25
Q

Langerhans cell histiocytosis

A. Most common extracutaneous involvement
B. Stain

A

A. Bone

B. S100+, CD1a+, CD207/Langerin+

26
Q

Stain for Xanthogranuloma

A

CD68+, CD207/Langerin-

27
Q

True of False: Lipid profile is normal in half of the patients with Xanthelasma

A

True

28
Q

Treatment of choice for Granuloma faciale

A

Glucocorticoids

29
Q

Treatment of choice for EED

A

Dapsone

30
Q

Sweet Syndrome

A. Associated malignancy
B. Treatment

A

A. Acute myelogenous leukemia (esp ulcerative/bullous type)
B. Systemic steroids

31
Q

Treatment of choice for Well’s disease

A

Systemic steroids

32
Q

Leukocytoclastic vasculitis

A. Clinical characteristic
B. Size of involved vessel

A

A. Palpable purpura

B. Small vessel vasculitis

33
Q

Identify the deposition in the following diseases:

A. Rheumatoid nodule
B. Gout
C. Granuloma annulare
D. Necrobiosis lipoidica

A

A. Fibrin
B. Monosodium urate crystals
C. Mucin
D. Dead collagen

34
Q

Bullous Lupus Erythematosus

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal (sublamina densa)
B. Neutrophil
C. Continuous homogenous granular IgG > IgA, IgM, C3 along the DEJ
D. Floor/dermal side
E. Collagen 7 (290 kD)
F. Associated with systemic lupus erythematosus
G. See LE treatment algorithm

35
Q

Linear IgA Bullous Dermatosis / Chronic Bullous Disease of the Childhood

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal
B. Neutrophil
C. Linear IgA along DEJ
D. Roof or Floor or Both
E. BPAG2 specifically LAD1 (120 kD) and 97 kD cleaved portion
F. Drug (Vancomycin), PCN, CPN
G. Dapsone

36
Q

Dermatitis Herpetiformis

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal (papillary dermis)
B. Neutrophil
C. Granular or Fibrillar IgA along DEJ
D. -
E. Epidermal transglutaminase 3
F. Gliadin (antigenic component of Gluten)
G. Gluten-free diet (wheat, rye, barley), Dapsone

37
Q

Bullous Pemphigoid

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal (lamina lucida)
B. Eosinophil
C. Linear C3 > IgG along DEJ
D. Roof of the split/epidermal side
E. BPAG2 (180 kD) NC16A domain / COL17 > BPAG1 (230 kD)
F.
G.

38
Q

Porphyria Cutanea Tarda

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal
B. Non-inflammatory
C. Thick, waxy, homogenous deposits of anti-type IV collagen antibody of IgG and C3 at the DEJ and blood vessel walls
D. -
E.
F.
G.

39
Q

Epidermolysis Bullosa Acquisita

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal (sublamina densa)
B. Cell poor
C. Linear IgG > C3, IgA along DEJ
D. Floor of the split/dermal side
E. Collagen VII (290 kD)
F.

40
Q

Cicatricial pemphigoid

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal
B. Neutrophil
C. Linear C3 and IgG along DEJ
D. Floor of the split/dermal side
E. BP180, Laminin 332 (Epiligrin or Laminin 5), and Beta-4-integrin
F.
G.

41
Q

Bullous Erythema Multiforme

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subepidermal
B. Neutrophil
C. Granular C3 and IgM along DEJ
D. Floor of the split/dermal side
E. -
F.
G.

42
Q

Darier Disease

A. Mutation
B. Mode of inheritance
C. Histologic finding
D. DIF

A

A. ATP2A2
B. Autosomal dominant
C. Suprabasal split, more dyskeratosis, corp ronds (spinous layer) and grains (granular layer)
D. Negative

43
Q

Hailey-Hailey Disease

A. Mutation
B. Mode of inheritance
C. Histologic finding
D. DIF

A

A. ATP2C1
B. Autosomal dominant
C. Intraepidermal split with acantholysis at all level of the epidermis (“dilapidated brick wall”), less dyskeratosis
D. Negative

44
Q

Pemphigus vulgaris

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment
H. Substrate varianr

A

A. Suprabasal
B. -
C. Intercellular IgG, C3 on the epidermal keratinocytes
D.
E. Desmoglein 3 > Desmoglein 1 (160 kD)
F. Associated with myasthenia gravis, thymoma, autoimmune thyroiditis
G.
H. Monkey esophagus

45
Q

Acute Generalized Exanthematous Pustulosis

A. DIF
B. Most common offending drugs

A

A. Negative
B. Beta blockers, Cephalosporins, Calcium channel blockers, Macrolides

46
Q

DIF of Sneddon-Wilkinson Disease

A

Negative

47
Q

Pemphigus Foliaceus

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Subcorneal
B.
C. Intercellular IgG, C3
D.
E. Desmoglein 1 (160 kD)
F.
G.

48
Q

Etiologic agent of bullous impetigo

A

Staphylococcal exfoliatin A

49
Q

Stevens-Johnson Syndrome

A. Site of split
B. Predominant cell
C. DIF
D. IIF/Salt-Split Skin
E. Antigen
F. Etiology/Trigger
G. Treatment

A

A. Full thickness epidermal necrosis
B. -
C. Negative
D. -
E. -
F. Sulfonamides, Carbamazepine (HLAB1502), Allopurinol (HLAB5801)
G. Supportive

50
Q

Stain for Stasis Dermatitis and Pigmented Purpuric Dermatosis

A

Perl Stain (Blue)

51
Q

First line treatment of PRP

A

Acitretin

52
Q

Psoriasis vulgaris

A. Strongest association
B. Earliest histopath change
C. Offending drugs

A

A. HLAcw6
B. Dilated blood vessels
C. Lithium, Beta blockers

53
Q

Most common etiology of erythema multiforme

A

Recurrent HSV infection

54
Q

Common offending drugs that cause fixed drug eruption

A

NSAIDs - lips
Sulfonamides - genitalia

55
Q

Syphilis

A. Etiologic agent
B. Stain
C. Treatment
D. Tests

A

A. Treponema pallidum
B. Warthin Starry
C. Benzathine penicillin G 2.4 million units IM
D. Non-Treponemal: VDRL & RPR
Treponemal: FTA-ABS & MHA-TP

56
Q

Stain for mycosis fungoides

A

CD3+, CD20-

Others: CD4, CD5, CD7, CD8

57
Q

Subtype of porokeratosis that is highly associated with malignant degeneration

A

Linear

58
Q

Stain for discoid lupus erythematosus

A

Basement membrane: PAS
Mucin: Alcian blue, Colloidal iron, Toluidine blue, Mucicarmine

59
Q

Patterns of Grover Disease

A

Darier Disease (most common)
Hailey-Hailey Disease
Pemphigus (vulgaris and foliaceus)
Sudoriferous acrosyringeal acantholytic disease
Spongiotic

Dermpath (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions